EU research results


English EN

INSIGHT FOR EYESIGHT – Novel mRNA medicines for eye disease


Proper eyesight is essential for nearly all aspects of our life. Yet, over 4 million people suffer from reduced eyesight or blindness worldwide each year (30 million blind or partially sighted in EU, 1 in 3 senior (65+) EU citizens faces sight loss). Common reasons include glaucoma, cataract, macular degeneration, diabetic retinopathy, corneal injury and inflammation, as well as complications of surgery of the eye and physical injury. Despite continuous improvements in treatment of various underlying causes, much is still to be gained in the promotion of healing of damaged eye tissue. While the patient suffers pain, loss of quality of life and participation in society, socio-economic costs include increased reliance on care-takers, increased healthcare cost and burden. Overall, the societal cost of eye disease is estimated to around 200 €Bn for the developed world.
We envision the development of novel drug candidates, based on Mercurna’s proprietary messenger RNA (mRNA)-delivery platform, for greatly improved treatment of eye disease. A particularly interesting opportunity to explore in this project, is the use of mRNA to accelerate healing of the eye, a strategy that is applicable to multiple causes of eye disease. For this project, we aim to hire a researcher with a skillset and knowledge in the field of ophthalmology, who can critically strengthen Mercurna’s Innovation potential in this area.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries




Hertogplein 24
6511 Sk Nijmegen


Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 75 937,50

Project information

Grant agreement ID: 861897


Grant agreement signed

  • Start date

    15 October 2019

  • End date

    14 October 2020

Funded under:


  • Overall budget:

    € 75 937,50

  • EU contribution

    € 75 937,50

Coordinated by: